International Journal of Obesity (2010) 1–14
& 2010 Macmillan Publishers Limited All rights reserved 0307-0565/10 $32.00
www.nature.com/ijo
REVIEW
Changes in neurohormonal gut peptides following
bariatric surgery
CN Ochner1,2, C Gibson1, M Shanik3, V Goel1 and A Geliebter1,2
1
New York Obesity Research Center, Department of Medicine, St Luke’s-Roosevelt Hospital Center, Columbia University
College of Physicians and Surgeons, New York, NY, USA; 2Department of Psychiatry, Columbia University College of
Physicians & Surgeons, New York, NY, USA and 3Division of Endocrinology, North Shore-Long Island Jewish Health System,
Lake Success, NY, USA
The rising prevalence of obesity has reached pandemic proportions, with an associated cost estimated at up to 7% of health
expenditures worldwide. Bariatric surgery is currently the only effective long-term treatment for obesity and obesity-related
co-morbidities in clinically severely obese patients. However, the precise physiological mechanisms underlying the postsurgical
reductions in caloric intake and body weight are poorly comprehended. It has been suggested that changes in hormones
involved in hunger, food intake and satiety via the neurohormonal network may contribute to the efficacy of bariatric
procedures. In this review, we consider how gastrointestinal hormone concentrations, involved in appetite and body weight
regulation via the gut–brain axis, are altered by different bariatric procedures. Special emphasis is placed on neurohormonal
changes following Roux-en-Y gastric bypass surgery, which is the most common and effective procedure used today.
International Journal of Obesity advance online publication, 13 July 2010; doi:10.1038/ijo.2010.132
Keywords: brain; hormone; RYGB; ghrelin; GLP-1; PYY
Introduction
Obesity continues to increase in prevalence globally and is
associated with the metabolic syndrome as well as chronic
diseases, such as diabetes, hypertension and heart disease.1
The etiology of obesity is multifactorial, and levels of
appetite-related gut peptides have been shown to be related
to body weight.2 With the increase in obesity and the
associated morbidity and mortality, research into the contribution of hormones involved in energy homeostasis and
metabolism has also increased in recent years. As the number
of bariatric procedures has risen concurrently with the rise
in severe obesity, greater attention is being paid to how such
procedures may affect appetite-related hormones, which is
the focus of this review.
Appetite control and feeding behavior are regulated in part
by hormones released from the gut that activate areas of the
brain primarily located within the limbic and mesolimbic
systems.2 Along with other areas within the dopaminergic
reward pathway, the hypothalamus has been extensively
Correspondence: Dr C Ochner, NY Obesity Research Center, St Luke’sRoosevelt Hospital Center, 1111 Amsterdam Avenue, Babcock 1020,
New York, NY 10025, USA.
E-mail: co2193@columbia.edu
Received 2 February 2010; revised 4 April 2010; accepted 12 May 2010
linked to the control of food intake and energy homeostasis.3 The hormonal signaling network, which provides
information to the brain (primarily the hypothalamus)
about energy stores and metabolic status includes leptin
from fat stores and insulin from the pancreas as well
as cholecystokinin (CCK), glucagon-like peptide-l (GLP-1),
peptide YY3–36 (PYY3–36) and ghrelin from the gastrointestinal (GI) tract. Ghrelin is known to stimulate appetite
whereas cholecystokinin, GLP-1 and PYY3–36 promote satiety. Adipose tissue provides hormonal signals via leptin and
insulin to the brain about energy stores, and likely from
adiponectin and resistin.4 Enterokines from the gastrointestinal tract and adipokines from fat work together to regulate
short- and long-term food intake, respectively.
Surgical intervention for weight loss
Relative to behavioral interventions, surgical interventions
produce greater weight loss in both the short and long term.5
The currently employed surgical interventions for obesity all
contain a restrictive component, limiting the amount of
food that can enter the stomach pouch. Several procedures,
most notably Roux-en-Y gastric bypass (RYGB), also contain
a malabsorptive component, in which the bowel length is
Gut peptides in bariatric surgery
CN Ochner et al
2
shortened, decreasing nutrient and calorie absorption.
However, there is some question as to the degree and
durability of postsurgical malabsorption associated with
these procedures.6 A number of studies have attempted to
assess the mechanisms that lead to postsurgical reductions in
body weight and associated medical comorbidities, which
can occur before significant weight loss. The majority of
these studies implicate postsurgical changes in appetiterelated hormone levels.5
The reduction in caloric intake seen following bariatric
surgery is likely due to more than just the physical changes
made to the gastrointestinal tract.7 However, the precise
mechanisms of action are not well understood, particularly
with RYGB.8 An increasing number of studies suggest that
postsurgical changes within the neurohormonal system
may account for a proportion of postsurgical weight loss.9
Gastrointestinal hormone levels are often altered following
bariatric procedures and may contribute to postsurgical
reductions in caloric intake and body weight. For example,
postsurgical reductions in ghrelin, and earlier and enhanced
postprandial elevations of PYY and GLP-1, may reduce
hunger and promote satiety.10 Recent evidence also
suggests that postsurgical changes in such hormones
may lead to changes in brain activation in response to
appetitive cues.11
Surgical techniques
Most purely restrictive procedures create a small gastric
pouch with a narrow outlet, limiting the intake of food
without disruption of the absorptive function of the small
intestine. Vertical banded gastroplasty (VBG) and adjustable
gastric banding (AGB) are examples of purely restrictive
procedures. In VBG, the cardia of the stomach is sectioned
off by a longitudinal staple line with a tight outlet wrapped
by a band or mesh (Figure 1a). Adjustable gastric banding, on
the other hand, partitions the upper stomach using a tight,
adjustable, prosthetic band (Figure 1b). Laparoscopic adjustable gastric banding (LAGB) has progressively replaced VBG
as the most commonly performed purely restrictive bariatric
procedure due to its simplicity and lower complication
rate.12 Other restrictive procedures include sleeve gastrectomy, intragastric balloon, and endoluminal gastroplasty.
Malabsorptive procedures are primarily designed to bypass
a portion of the small intestine, reducing the efficiency of
nutrient absorption. The jejunoileal bypass is an example of
a purely malabsorptive procedure, which consists of dividing
the jejunum near the ligament of Treitz and reconnecting it
near the ileocecal valve, bypassing a long small bowel
segment (Figure 2a). However, this procedure is no longer
performed due to significant complications and relatively
greater need for revision surgeries.13
A combination of restrictive and malabsorptive techniques
is employed in several procedures, including the biliopancreatic diversion (BPD), biliopancreatic diversion with
duodenal switch (BPD-DS) and RYGB. With the BPD
procedure, there is a partial gastrectomy with a gastroileostomy or gastrojejunostomy, where a short bowel channel
is attached to a long Roux-Y limb for nutrients and
biliopancreatic secretions to be absorbed (Figure 2b). The
BPD is also limited in use due to adverse health outcomes
related to essential nutrient malabsorption.14 The BPD-DS is
a partial sleeve gastrectomy with an intact pylorus and a
Roux limb with short bowel channel (Figure 2c). This
procedure may be attractive to super-obese patients
(BMI450 kg m2), as it typically leads to relatively large
postsurgical weight loss; however, it is not commonly
performed due to adverse health outcomes similar to
those seen in BPD.13 Lastly, RYGB surgery is the most
common bariatric procedure performed today, accounting
for approximately 65% of all procedures worldwide.15
With this operation, a small gastric pouch is created and
Figure 1 Illustrations of restrictive procedures and Roux-en-Y gastric bypass. Reproduced with permission from Dr Edward C Mun.173 (a) Vertical-banded
gastroplasty; (b) Adjustable gastric banding; (c) Roux-en-Y gastric bypass.
International Journal of Obesity
Gut peptides in bariatric surgery
CN Ochner et al
3
Figure 2 Illustrations of malabsorptive procedures. Reproduced with permission from Dr Edward C Mun.173 (a) Jejunoileal bypass; (b) Biliopancreatic diversion;
(c) Biliopancreatic diversion with duodenal switch.
connected to a short Roux-en-Y alimentary limb of distal
small bowel, which is anastomosed to the jejunum, bypassing the duodenum and proximal jejunum (Figure 1c).
Gut and peripheral hormones as key appetite
regulators
Hunger and satiety are mediated through a complex interplay of neurological and hormonal signals.2,3 The hypothalamus processes many of these signals in relation to nutrient
and energy availability.3 Neural communication takes place
between the hypothalamus and other brain regions (including cortical areas), which send effector responses to regulate
food intake according to caloric need.3,11,16 There are three
different sets of signals from the periphery responsible
for providing this information: one from adipose tissue that
exerts long-term regulatory mechanisms on food intake, and
the other two from the GI tract, with orexigenic as well as
anorexigenic properties that exert primarily short-term
effects on food intake.17 Afferent signals can also result from
direct mechanical stimulation of the GI tract, such as gastric
distension due to stretch and pressure in the stomach.16,18
Ghrelin is an orexigenic peptide that can send signals to
the hypothalamus via blood circulation as an endocrine
hormone, through vagal afferents containing ghrelin receptors, or via release within the hypothalamus.19 Neuropeptide
Y (NPY) and agouti-related protein-producing neurons in the
arcuate nucleus of the hypothalamus are stimulated by
ghrelin to increase food intake.17 Other peripheral hormones
have been shown to induce satiety signals that can act
directly on the brain, indirectly via the vagus nerve, or by
slowing gastric emptying. These satiety hormones include
CCK, GLP-1 and PYY, which rise after meals, and can
suppress food intake when administered peripherally or
centrally.17
Gut and peripheral hormones in relation to
bariatric surgery
The seeming inability of the rearrangement of gut anatomy to
fully explain the sustained reductions in body weight and
medical comorbidities seen following bariatric surgery has
inspired a body of literature on postsurgical changes in
appetite-related hormones. Gut peptides known to cross the
blood–brain barrier and induce changes in neural activation are
likely candidates to account for the currently unexplained
effects of bariatric surgery.8,9 Ghrelin, PYY, GLP-1, CCK, insulin
and leptin are released in the periphery and act indirectly on
the vagus nerve and/or directly on target areas of the
hypothalamus.20 Thus, this review focuses on recent literature
reporting postsurgical changes in appetite hormones that have
been linked to hypothalamic targets. Bariatric surgery can also
alter the concentrations of other gut hormones such as gastrin,
gastric inhibitory polypeptide, serotonin, neurotensin and
vasoactive intestinal peptide. However, these hormones do
not have substantiated effects on food intake and will not be
discussed.
Search/inclusion criteria for studies of gut
hormones following bariatric surgery
A literature search was conducted between February 2009
and July 2010. Articles were collected from Medline,
PubMed, PsychINFO and TRIP databases. Articles were also
identified from UpToDate Inc. published research and
reviews. Because the primary aim of this review was to
examine changes observed in gut hormones from before
to after bariatric surgery, only articles that included measures
of gut peptides involved in appetite control were included.
No restrictions in terms of participant randomization or
blinding were placed on included studies, and no restrictions
were placed on the year of publication; however, articles
International Journal of Obesity
Gut peptides in bariatric surgery
CN Ochner et al
4
published after July 2010 were not included. Literature
searches were conducted using various combinations of the
following key words: adiponectin, amylin, appetite, appetite
centers, appetite control, bariatric surgery, BPD, BPD-DS,
body weight, CCK, duodenal jejunal bypass (DJB), food
intake, gastric banding, gastric bypass, gastrointestinal
hormones, GLP-1, ghrelin, gut hormones, hypothalamus,
insulin, LAGB, leptin, metabolic surgery, neuroendocrine
peptides, neuronal activation, obesity, oxyntomodulin, PYY,
resistin, RYGB, and weight loss.
Table 1 Summary of GI hormone changes after restrictive surgical
procedures
Hormone
AGB c
Ghrelina
PYY3–36b
GLP-1b
CCKb
Leptina
Insulina
Ghrelin
Ghrelin is a potent appetite stimulator and an endogenous
ligand for the growth hormone secretagogue receptor. It is
mainly synthesized by the gastric antrum and fundus.
Injection of ghrelin centrally in animals stimulates the
release of the orexigenic neuropeptides NPY and agoutirelated protein-producing neurons, most notably in the
arcuate nucleus of the hypothalamus.21 Ghrelin enhances
gut motility and speeds gastric emptying.22 Ghrelin concentrations peak before meals and fall sharply postprandially,
and some data in humans implicate ghrelin’s involvement
in pre-meal hunger and meal initiation. Higher ghrelin
concentrations are noted during fasting, hunger or negative
energy balance states such as short-term starvation, cancer or
anorexia.22 Sustained ghrelin levels by infusion can induce
adiposity in animals23 and, thus, ghrelin may also have a role
in the long-term regulation of body weight.
Reduced ghrelin levels are observed after feeding, during
hyperglycemia, and in obesity.24 Fasting ghrelin has been
found to be 27% lower in obese as compared to normalweight individuals,25 and ghrelin concentrations rise
following weight loss.26 Despite having lower ghrelin levels,
overweight, obese and insulin-resistant individuals often
continue to gain weight. The lower fasting levels in obesity
suggests downregulation of ghrelin in response to overeating
or excess body weight.
In purely restrictive operations, the upper portion of
the stomach is reduced, with varied effects on ghrelin
levels depending on the type of procedure. Bohdjalian and
colleagues27 prospectively studied 26 patients who had
sleeve gastrectomy and showed that ghrelin concentrations
were reduced 12 months post-operatively and remained low
during a 5-year follow-up. A reduction in fasting ghrelin was
found in other studies after laparoscopic sleeve gastrectomy;28–31 however, increases in ghrelin following LAGB
have been reported.28,32–34 Similar variations in results were
noted after AGB and VBG (Table 1). The majority of studies
report an increase in ghrelin following both AGB28,32–35 and
VGB.34,36–38 However, nearly as many studies report no
change following either procedure,39–43 and two crosssectional studies have reported lower ghrelin concentrations
following AGB relative to BMI-matched controls.44,45
Inconsistent postsurgical changes in ghrelin have
also been found in malabsorptive procedures (Table 2).
International Journal of Obesity
Type of restrictive surgery
PPa
OXMb
Adiponectina
Resistina
Amylinb
m28,32–35
239–41
m45,193
241,51
k34,35,39,41,125
k34,41,137
239
239
m125,128,194
2195
m195
251
VBG d
SG e
m34,36–38
242,43
m91
m101
m112
2111
k34,37,42
k34,42
k27–31
k152
2153
2111
m37,42,196
2195
m195
2126
m92,126
m126
2126
k126
2126
2126
k126
2126
m ¼ postsurgical increase. k ¼ postsurgical decrease. 2 ¼ no significant
postsurgical change. aFasting (vs postprandial based on relevance to peptide
and majority of available studies). bPostprandial (vs fasting). cAGB ¼ adjustable
gastric banding. dVBG ¼ vertical banded gastroplasty. eSG ¼ sleeve
gastrectomy.
Table 2 Summary of GI hormone changes after malabsorptive surgical
procedures
Hormone
Type of malabsorptive surgery
c
GB (JIB , RYGB e, DJB f)
Ghrelina
PYY3–36b
GLP-1b
CCKb
Leptina
Insulina
PPa
OXMb
Adiponectina
Resistina
Amylinb
d
m4,48–51
k30,38,42,43,47,197
231,35,41,57
m30,31,41,51,57,92,94,102,103
m30,51,57,94,103,106,167,193,198–200
2111,129
k4,35,41,42,49,57,62,128,129
k4,41,42,57,62,106,127,129,137,141,197
257,201
248,150,151
m57,111,151,161,162
m4,42,62,106
24,166
k51
BPD g
m25,59,60
k42
250,58
BPD-DS h
k37,130
m101,140,199
k25,42,59
k42,140
k37,130
m42,130
m37,130
m ¼ postsurgical increase. k ¼ postsurgical decrease. 2 ¼ no significant
postsurgical change. aFasting (vs postprandial based on relevance to peptide
and majority of available studies). bPostprandial (vs fasting). cGB ¼ gastric
bypass. dJIB ¼ jejeunoileal bypass. eRYGB = Roux-en-Y gastric bypass. fDJB ¼
duodenal-jejunal. gBPD ¼ biliopancreatic diversion. hBPD-DS ¼ biliopancreatic
diversion -duodenal switch.
The majority of studies examining changes in ghrelin after
RYGB report a decrease in postsurgical circulating ghrelin
levels.4,30,38,42,43,46–51 In a cross-sectional comparison,
Cummings and colleagues52 found that ghrelin levels
were markedly reduced in post RYGB participants, as compared
to both obese and normal weight control participants.
Gut peptides in bariatric surgery
CN Ochner et al
5
They also reported that obese participants who had lost
weight by dieting had higher levels of ghrelin than they did
before dieting,52 suggesting that ghrelin may have a role in
the adaptive response that limits the amount of weight lost
by dieting and increases the likelihood of weight regain.
Subsequent to Cumming and colleagues52 findings, others
have also reported significantly lower levels of ghrelin in
patients who lost weight from RYGB in both cross-sectional
and prospective studies.30,38,42–44,46,47,53–56 Decreased ghrelin levels were also present within the first year following
BPD in two reports.42,44 These studies suggest that a
postsurgical reduction of ghrelin may contribute to the
sustained weight loss noted in obese patients following
gastric bypass. However, a number of researchers have found
no significant change in ghrelin levels following gastric
bypass31,35,41,57 and BPD,50,58 and higher ghrelin concentrations have also been reported following both RYGB4,48–50
and BPD.25,59,60
Variation in study results of ghrelin levels may be at least
in part explained by differences in the comparison groups
selected. Holdstock and colleagues61 prospectively studied
the effect of RYGB and found that levels of ghrelin increased
at 12 months and were similar to BMI-matched controls.
These RYGB patients underwent significant weight loss at 12
months, which would be expected to lead to a rise in ghrelin
levels. Had these operative patients been compared to
BMI-matched controls that had lost weight conventionally,
one might have expected a relatively lower ghrelin level in
the postsurgical patients. In a prospective study by Faraj and
colleagues,62 there was also a rise in ghrelin levels in patients
following RYGB undergoing active weight-loss. However,
there were no control participants, and, despite the increase
in ghrelin levels observed in the surgical patients, they were
still lower than levels reported in normal weight or
comparably obese participants from other studies.52,63
Cummings and colleagues64 suggest that the variance
across findings may also be related to the integrity of autonomic vagal innervation. Vagal innervation affects ghrelin
levels,19,65–67 and the degree to which the innervation is
left intact is likely to differ between surgeons. Despite the
inconsistencies, several key trends are apparent. First, the
type of surgical procedure seems to have a major influence
on ghrelin levels. The majority of studies examining changes
in ghrelin levels following RYGB report a postsurgical
decrease, whereas the majority of studies following
AGB report an increase (Tables 1 and 2). In RYGB, the
stomach antrum, fundus and duodenum, where most of the
production of ghrelin occurs,68,69 are largely excluded.
Thus, ingested nutrients have significantly less contact with
ghrelin-producing cells in the stomach and duodenum,
which may lead to an inhibition of ghrelin release. In
contrast AGB, which results in little or no reduction
in ghrelin (Table 1), does not exclude the fundus or
duodenum from contact with nutrients. This explanatory
hypothesis is consistent with Fruhbeck and colleagues54 who
showed decreased fasting concentrations after RYGB and an
increase after AGB as well as following conventional
comparable weight loss by diet in obese patients. The
reduction in postsurgical ghrelin levels in gastric bypass
may contribute to the greater weight loss relative to other
procedures.3,16
It should be noted that although the majority of studies
refer to total ghrelin, as described above, ghrelin has two
major molecular forms: acylated ghrelin and des-acylated
ghrelin. Acylated ghrelin, which induces a positive energy
balance and is suppressed post-prandially and by pharmacological hyperinsulinemia, was previously presumed to be the
only active form in terms of endocrine function. However,
des-acylated ghrelin makes up the vast majority of total
ghrelin,70 and there is increasing evidence in both animals71
and humans72,73 that des-acylated ghrelin may exert effects
in opposition to those exerted by acylated ghrelin. In
addition, hyperinsulinemic and hyperinsulinemic–hyperlipidemic clamp studies show suppression of des-acylated
ghrelin, but no change in acylated ghrelin, suggesting that
insulin regulation of ghrelin may be specific to des-acylated
ghrelin.74 Finally, recent evidence suggests that des-acylated
ghrelin binds specifically to HDL whereas acylated ghrelin
binds equally to all lipoproteins.75 Precisely how these two
distinct forms of the same peptide interact in the regulation
of energy balance remains under investigation, but illustrate
the need to examine all forms of appetite-related hormones
in the body.
Peptide YY
Although ghrelin has received the majority of the attention
in surgically induced weight loss studies, there has been a
shift in focus toward other hormones, such as PYY and GLP-1.
In contrast to ghrelin, which is an appetite-stimulating
hormone, PYY is a lower gut-derived hormone with
anorectic effects.17 It is secreted from intestinal L-cells in
amounts that generally correspond to the energy ingested;
however, the amount secreted may vary depending on
the macronutrient content of the ingested energy.76,77 PYY
circulates in two forms: PYY1–36 (total) and PYY3–36 (referred
to as ‘active’), with the latter being the major subtype found
in the circulation.78 PYY1–36 binds to Y1–Y5 receptors,79 and
there is contradictory evidence on the effect of PYY1–36 on
food intake.80–82 However, administration of PYY3–36 reduces
food intake over the short term in both animals78,83 and
humans.84 PYY3–36 likely reduces food intake by acting on Y2
receptors on vagal afferents, which results in increased
activity in the arcuate nucleus of the hypothalamus to
inhibit NPY activation.85 Appetite suppression by PYY3–36
may also result from slowing of gastric emptying (ileal brake
mechanism).86
Levels of PYY3–36 are low during fasting and peak 1–2 h
following food intake, with high fat foods resulting in the
greatest release of PYY3–36.87 Batterham and colleagues84
demonstrated lower premeal PYY3–36 levels in 12 obese as
compared to 12 lean participants, as well as a smaller
International Journal of Obesity
Gut peptides in bariatric surgery
CN Ochner et al
6
postprandial rise, suggesting that obesity may be associated
with a PYY3–36 deficiency. However, Pfluger and colleagues
found no significant difference in fasting PYY levels between
66 lean and 63 obese subjects.88 Nevertheless, obese
participants remain sensitive to the anorectic effects of
exogenously administered PYY3–36.89
The majority of evidence suggests that restrictive procedures lead to a rise in fasting and postprandial PYY.29–31,90–92
Fasting and postprandial PYY levels in clinically severely
obese surgical patients were comparable to non-obese
controls, following VBG in cross-sectional studies at 6
months and remained relatively constant at 12 months
post-surgery.91 Two studies have reported similar postprandial PYY3–36 levels in post AGB patients and lean
controls.45,93
Malabsorptive operations consistently demonstrate a
post-surgical increase in fasting and postprandial PYY
levels.30,31,41,51,57,90,92,94 In a cross-sectional study at 15–17
months post-RYGB, Korner and colleagues95 found an early
postprandial rise in PYY concentrations in 12 patients. In a
longitudinal study,41 PYY levels were significantly greater in
RYGB patients than in LAGB patients after 52 weeks, despite
little difference in BMI’s between the two post surgical
groups. The mechanism of this early and exaggerated
response may be due to the stomach and pylorus being
bypassed, which likely leads to faster transit to the lower gut.
Garcia-Fuentes and colleagues50 found that BPD produced an
even greater rise in PYY levels than RYGB.
An increase in postprandial PYY concentrations alone may
result in an early sense of satiety and reduced meal size, and
the combined effect of increased PYY and reduced ghrelin
(Tables 1 and 2) may contribute further to weight loss.31,55
PYY suppresses a high proportion of ghrelin-sensitive
neurons in the arcuate nucleus of the hypothalamus in a
dose-dependent manner.96 A shift in the ghrelin/PYY ratio in
favor of PYY after bariatric surgery may result in reduced
appetite. Further longitudinal investigations pre and post
surgery and across different operations are needed to clarify
this point.
Glucagon-like peptide 1
Glucagon-like peptide-l is a key incretin hormone coreleased with PYY from the distal intestinal L-cells of the
gut after a meal. It is secreted in two equally potent forms,
GLP-1 (7–37) and GLP-1 (7–36).97 The primary functions of
GLP-1 include the potentiation of glucose-stimulated insulin
secretion, enhancement of b-cell growth and survival,
inhibition of glucagon release, and control of food intake.98
Following peripheral administration of GLP-1, most studies
in humans report decreased food intake and increased
fullness.99 GLP-1 acts as an ileal brake for the upper GI tract
and reduces food intake in part by slowing gastric emptying,
resulting in greater gastric distension. Plasma levels of GLP-1
are higher both before and after food intake in lean
as compared to obese individuals, who have lower fasting
International Journal of Obesity
GLP-1 and an attenuated postprandial release.100 Relatively few
studies have examined changes in GLP-1 concentrations in
obese patients after restrictive bariatric procedures. With
respect to AGB, two studies have reported no postsurgical
change in fasting GLP-1.39,41 However, Reinehr and colleagues90 found that fasting GLP-1 was reduced in AGB patients
at 2-year post-surgery. Conversely, an increase in fasting and
postprandial GLP-1 has been reported in one study29 following sleeve gastrectomy. Other investigators showed that GLP-1
levels during an oral glucose tolerance test were increased in
VBG and BPD, with a greater increase in BPD relative to
VBG.101 GLP-1 is secreted from the distal small bowel;
therefore restriction of the stomach would not be expected
to have a major impact on circulating levels of GLP-1.
Postsurgical increases in postprandial GLP-1 have
been documented following malabsorptive operations.30,31,
41,51,57,94,102,103
Morinigo and colleagues94 found that RYGB
leads to a significant increase in postprandial GLP-1 levels 6
weeks postoperatively, when participants were still markedly
obese. Elevated levels of GLP-1 may contribute to the
sustained efficacy of RYGB as well as improve and resolve
diabetes, consistent with the mechanisms underlying this
incretin’s effect on weight and glucose metabolism.104 RYGB
reduces the size of the stomach and bypasses the duodenum,
which allows for faster delivery of food contents through the
gut,105 enhancing GLP-1’s effect. Dramatic increases in GLP
levels have been observed immediately after RYGB,94 which
may be due to foregut exclusion and/or rapid hindgut
delivery.104 Long term follow-up with bariatric surgical
patients may be informative about whether treatment with
GLP-1 analogs for diabetes is sustainable. As with PYY3–36,
it has been suggested that increased hypothalamic satiety
signals resulting from increases in postprandial GLP-1 may
contribute to some of the postsurgical weight loss following
malabsorptive procedures.94,106
Cholecystokinin
Cholecystokinin, an endogenous peptide hormone present
in the gut and the brain, helps control appetite, ingestive
behavior, and gastric emptying via both peripheral and
central mechanisms. CCK is also known to have a number of
effects on physiological processes including anxiety, sexual
behavior, sleep, memory and intestinal inflammation.107
CCK is actually a collection of hormones labeled according
to number of amino acids (for example, CCK 8 in the brain,
CCK 33 and CCK 36 in the gut); however, differential effects
on human energy balance have not been well established.
Therefore, in keeping with convention, we refer to CCK in
the singular. CCK originating from the gut is rapidly released
from the duodenal and jejunal mucosa in response to
nutrients, peaks at about 15–30 min and remains elevated
for up to 5 h postprandially.108 It is a potent stimulator of
pancreatic digestive enzymes and bile from the gall bladder.17 It delays gastric emptying and promotes intestinal
motility. As a neuropeptide, CCK activates receptors on vagal
Gut peptides in bariatric surgery
CN Ochner et al
7
afferent neurons, which transmit satiety signals to the
dorsomedial hypothalamus. This action suppresses NPY
and provides feedback to reduce meal size and meal
duration.109
Studies of postsurgical changes in CCK are sparse, and the
interpretation of early studies is somewhat hampered by
difficulties associated with previous assay techniques due to
low plasma concentrations, extensive molecular heterogeneity and close homology of CCK to gastrin, which circulates
in higher concentrations.110 Reported changes following
bariatric surgery are variable in both restrictive and malabsorptive procedures (Tables 1 and 2). One study compared
CCK levels after a glucose or protein meal before and after
RYBG and VBG, and the CCK response was not affected by
either procedure.111 However in another study, Foschi and
colleagues112 compared patients before and after VBG
surgery with healthy lean volunteer controls and found
that post-VBG patients had a higher peak CCK response to
an acidified meal known to increase CCK production113 and
a faster time to the peak than controls, without differences
between baseline CCK concentrations.112 In rats, CCK was
not significantly altered after RYGB-induced weight loss.109
However, Baldinger and colleagues105 found a greater
increase in CCK following RYGB in humans, as well faster
emptying which are consistent as nutrients reaching the gut
stimulate CCK. Although a reduction in CCK following
RYGB might be expected due to the diversion of ingested
food away from the upper part of the small intestine (the
duodenum), the jejunum also releases CCK.114
In contrast to leptin and insulin,115 CCK does not appear
to have an independent role in the long-term regulation of
energy balance and body weight,116 but rather a primary role
in short term control of appetite and satiety.117 CCK can
work synergistically with leptin to enhance short-term
reduction of food intake in mice.118 There is also novel
work indicating that high insulin levels may increase
circulating CCK via insulin-induced suppression of free fatty
acids, with lipid infusion abolishing these effects.119 As such,
changes in macronutrient absorption after bariatric surgery
affecting glucose- and protein-induced insulin secretion may
contribute to altered circulating CCK levels, with potential
effects on short-term satiety and gastric emptying. However,
CCK’s precise role in human obesity remains somewhat
unclear, and more work is needed in examining changes in
CCK following bariatric surgery.
Leptin
Leptin is produced primarily in the adipose tissue. It is
categorized as an adipokine and plays a large role in the
regulation of energy balance. Leptin produced from adipocytes sends signals about energy status from the periphery to
hypothalamic regulatory centers.17 In humans, serum leptin
levels rise or fall in response to acute caloric surplus or
deficits, respectively. Leptin administration has anorexigenic
effects in both animals and humans,17,20 although much less
effective in humans.120 Leptin also helps control adipose
metabolism in the body by stimulation of lipolysis and
suppression of lipogenesis.121 Fasting serum leptin is higher
in the obese due to the presence of more body fat, the main
source of leptin.121 Consistent with this, leptin decreases
with weight and fat loss.122 Following meals, leptin increases
slowly and may make only a small contribution to shortterm satiety, but a larger one to long-term body weight
regulation.123 Nevertheless, leptin injections in obese humans have not been efficacious in reducing food intake and
body weight, likely due to the development of leptin
resistance.123 It should be noted that leptin has also been
found to be secreted from the gastric mucosa, but in much
lesser amounts than from adipose tissue.124 Although leptin
secreted from adipocytes acts primarily on the hypothalamus for long-term regulation of food intake, gastric leptin is
involved in the short-term regulation of digestion, including
the delay of gastric emptying, absorption of nutrients by the
intestinal wall and, the secretion of gastric, intestinal, and
pancreatic hormones.124
As expected, fasting leptin levels consistently decrease57
following bariatric surgery in relation to fat loss, irrespective
of procedure.4,25,34,35,37,39,41,42,59,62,125–130 Relative to presurgical levels, lower postprandial leptin levels have also
been reported in obese patients after VBG.131 A similar
reduction was found at 2 and 12 months post BPD as
compared to pre-surgery.59 Plasma leptin concentrations
were also lower in clinically severely obese patients who
underwent BPD-DS.37,130 Finally, Rubino and colleagues129
found that leptin levels were reduced following gastric
bypass as with non-surgical weight loss.37 Recent evidence
suggests that leptin-replacement therapy may aid in weight
loss maintenance.132,133
Insulin
Insulin is a pancreatic hormone that maintains glucose
homeostasis and was the first identified adiposity signal.
Insulin levels rise after a meal to optimize glucose use for
energy. The excess glucose is converted and stored in the
liver and muscle as glycogen, and as fat in adipose tissue.
Insulin concentrations vary directly with adiposity, and
visceral fat is negatively correlated with insulin sensitivity.134
Fasting and postprandial insulin are higher in obese than in
lean individuals.135 Insulin can penetrate the blood–brain
barrier and binds to receptors in the arcuate nucleus to
decrease food intake.136
In addition to its interactive effects with other hormones
mentioned above, insulin itself is a long-term regulator of
body weight, and, in the majority of restrictive bariatric
operations, insulin tends to fall in post-surgical obese
patients.34,41,42,126,137 Reductions in postsurgical levels of
circulating insulin were maintained at 2-year post GB
and VBG,34 and obese patients had lower insulin levels
after LAGB than BMI-matched controls.138 Weight loss,
secondary to gastric bypass and BPD, improves insulin
International Journal of Obesity
Gut peptides in bariatric surgery
CN Ochner et al
8
resistance.42,62,137,139,140 However, Korner and colleagues95
showed that insulin levels were decreased in surgically treated
obese women with RYGB in comparison to BMI-matched obese
counterparts. Insulin levels and resistance were also significantly lowered in obese individuals with and without Night
Eating Syndrome 5 months after RYGB.141 These operations are
being further investigated as a potential treatment for diabetes
as an alternative to pharmacological agents.142
Other gut hormones
Other gut signals that regulate body weight through
stimulation of hypothalamic regions include but are not
limited to pancreatic polypeptide,143 oxyntomodulin,144
adiponectin,145 resistin,146 and amylin.147 Pancreatic polypeptide has structural similarities with PYY and NPY. It is
secreted from pancreatic cells in relation to caloric ingestion
and can remain in the bloodstream for up to 6 h postprandially.148 It is also involved in gallbladder relaxation and
inhibition of pancreatic secretion. Once secreted, the binding action of this enteroendocrine hormone to Y4 receptors
in the arcuate nucleus of the hypothalamus has been
implicated in the suppression of food intake in mice.143
Few studies have looked at pancreatic polypeptide following
obesity surgery, but most show that bariatric surgery has
only minimal influence.29,39,48,149–154
Oxyntomodulin (OXM) is co-secreted with GLP-1 from the
enteroendocrine L cells to suppress the acid-producing oxyntic
glands of the stomach.155 Central injection of OXM reduces
food intake and weight gain in rodents and has been shown to
reduce hunger and food intake in humans.156 Oxyntomodulin
also has an incretin effect following glucose intake similar to
GLP-1.157 Central intravenous OXM infusions in the rat
hypothalamus reduced food intake,158 and intraperitoneal
administration of OXM in rodents suppressed fast-induced
and dark-phase food intake.159 In one study, an increase
in OXM precursor gene (pre-proglucagon) expression was
observed after an ileal transposition in a rat model.160 Levels of
OXM increased in the majority of bypass operations,57,111,161,162 whereas no significant changes in OXM
levels were observed following VBG.111
Adiponectin is a peptide produced and released exclusively
by adipose tissue, in this respect similar to leptin. However,
plasma levels of adiponectin remain relatively constant
throughout the day and are not affected by food intake.17
Furthermore, there is a negative correlation between BMI and
plasma levels of adiponectin.4 Obese individuals with diabetes
have even lower plasma levels of adiponectin than nondiabetic obese individuals,4,42 which suggests that diminished
adiponectin may contribute to insulin resistance. A dramatic
increase has been found in adiponectin levels after RYGB in
obese patients.4,42,62,106,163 Adiponectin levels also increased
after weight loss following a BPD-DS procedure.37,130
Resistin, also known as adipose tissue-specific secretory
factor, is another adipokine hormone that acts on skeletal
muscle myocytes, hepatocytes, and adipocytes. Opposite
International Journal of Obesity
in effects to adiponectin, higher resistin may contribute to
insulin resistance.4 Resistin is positively correlated with
obesity in animal studies,164,165 but there is contradictory
evidence about its role after weight loss induced by diet or
surgery in humans.4,163,166 Amylin, which is co-secreted with
insulin from the pancreas, is considered a major satiety
peptide, and was recently found to be decreased after a 12 kg
weight loss following gastric bypass surgery in obese
individuals.51
Discussion
Similar postsurgical changes have been found between
restrictive and malabsorptive procedures in levels of leptin,
insulin, and adiponectin, suggesting that these hormonal
changes may result primarily from the associated weight
loss.41,42 Differences between these procedures in their
effect on other appetite-related hormone levels that may
contribute to the generally superior effectiveness of combination procedures over purely restrictive procedures are
more difficult to assess, but in general show differences
between procedural types on changes in ghrelin and GLP-1.
Most studies show a postsurgical decrease in levels of the
orexigenic hormone ghrelin following gastric bypass
procedures,38,42,43,46,47 but a postsurgical increase in ghrelin
levels following gastric banding.32,34,36–38,46 In addition,
most studies of the anorexigenic hormone, GLP-1,
reveal significant increases following bypass procedures51,94,106,167,168 but no change following banding.39,41,51
With regard to PYY, most studies show a postsurgical
increase in postprandial PYY in malabsorptive31,41,90,94 and
some restrictive (VGB, sleeve gastrectomy)29,91 procedures;
however, it remains unclear whether AGB has any significant
effect on postprandial PYY levels.41
These general findings suggest potential mechanisms by
which bypass patients would experience less hunger, as well
as greater and sooner postprandial fullness as compared
to banding, thus contributing to greater weight loss. The
bypassing of the stomach and upper intestine may promote
faster gastric emptying. More rapid transit of nutrients
through the lower gut may stimulate a faster and enhanced
postprandial release of gut peptides, and enhance the effect
of the ileal break mechanism.7
Roux-en-Y gastric bypass remains the most commonly
performed and effective bariatric procedure used today;
however, its mechanisms may be the least well understood.
Recent evidence suggests that the restrictive and malabsorptive components alone are insufficient to account for the
resulting weight loss.7,8,169,170 Currently, sufficient data are
not available to quantify the individual contributions to
postsurgical weight loss of the restrictive and malabsorptive
components of RYGB surgery. Through comparisons with
VGB, it may be possible to crudely estimate the magnitude of
postsurgical weight loss not accounted for by the restrictive
Gut peptides in bariatric surgery
CN Ochner et al
9
mechanism in RYGB. The comparison with VGB was chosen
over AGB, as VGB involves sectioning of the stomach (as
opposed to banding) and the level of restriction in VGB may
better approximate that of RYGB.52,171
In prospective randomized trials, 50–80% loss of excess
body weight was seen 1–2 years following RYGB, as opposed
to only 30–50% 1 to 2 years after VBG, suggesting that
0–50% (Low end point of range (0%) determined by subtracting the highest % excess body weight loss following VGB
from the lowest % excess body weight loss following
RYGB (50% 50% ¼ 0%). High end point of range (50%)
determined by subtracting the lowest % excess body weight
loss following VGB from the highest % excess body weight
loss following RYGB (80% 30% ¼ 50%)) of the weight loss
seen following RYGB may be left unexplained by the
restrictive component. A meta-analysis comparing RYGB to
VGB confirms that the short-term (1–2 years) disparity
between procedures is approximately 25%,172 suggesting
that the restrictive component accounts for up to 75% of
post-RYGB weight loss. However, longer-term data suggests a
greater disparity between these procedures.173 A nearly 80%
failure rate (failure to maintain the loss of at least half of
excess body weight) has been reported after 10 years with
VGB,12 and both cross-sectional and prospective studies
suggest that the disparity between RYGB and VGB may
increase over time due to the superior weight loss maintenance following RYGB.169,171,174–176 In addition, it is
important to note that estimating the effect of gastric
restriction itself by comparisons with VGB would hold true
only if weight loss seen following VGB were achieved
independent of changes in gut peptides. However, several
postsurgical changes in gut peptides have been noted
following VGB, such as increases in postprandial PYY3–3691
and GLP-1,101 and may account for a proportion of
postsurgical weight loss. Therefore, we feel it reasonable
to estimate that the restrictive component may account for
50–75% of post-RYGB weight loss.
Although a clear effect of malabsorption can be seen in
weight loss resulting from procedures such as jejunoileal
bypass and BPD, clinically significant malabsorption, measured by indices such as albumin, prealbumin and fecal fat,
is not observed after the standard proximal RYGB.7,177–180
In addition, several animal studies181–184 have shown that
sleeve gastrectomy with ileal transposition, a new procedure
designed to combine gastric restriction with intentional
changes in gut peptide profile (earlier and exaggerated
release of GLP-1 & PYY, lower ghrelin, etc.) while avoiding
nutrient malabsorption, shows weight loss equal to that seen
following RYGB. Initial studies in humans suggest similar
findings with sleeve gastrectomy with ileal transposition.
For example, Gagner et al.185 reported that individuals
undergoing sleeve gastrectomy with ileal transposition as a
revision surgery of BPD-DS showed completely restored gut
absorptive function while maintaining weight loss.
Rubino and Marescaux186 found no reduction in food
intake or body weight in rats undergoing gastrojejunal
bypass, which involves a bypass of approximately the same
amount of intestinal foregut as is excluded in RYGB but
spares the stomach, as compared to sham-operated rats.
Finally, malabsorptive effects of only 4% have been shown in
animal models187 and similarly modest effects have been
postulated in humans.7,35,181,188 Thus, a rough estimate of
5% of weight loss attributable to the malabsorptive component of RYGB may be reasonable.
Together, the estimated percentages of post-RYGB weight
loss attributable to gastric restriction (50–75%) and malabsorption (B5%) suggest that the restrictive and malabsorptive
components combined account for approximately 55–80% of
weight lost through RYGB. Thus, approximately 20–45% of
post-RYGB weight loss may be currently unexplained.
Increases in resting energy expenditure have been raised as a
potential contributing mechanism.187,189 However, evidence
appears to indicate the REE decreases postsurgically in
proportion to fat loss.190,191 Similarly, dumping syndrome
was proposed as an additional potential mechanism; however,
severity of dumping syndrome correlates poorly with weight
loss,7 rendering it unlikely to play a significant role in the
efficacy of RYGB. Therefore, an estimated 20–45% of weight
loss secondary to RYGB surgery could be explained by other
factors,192 a large percentage of which may be attributable to
the associated neurohormonal changes discussed in this
review, leaving the potential open for substantial and
sustainable weight loss effects if these neurohormonal effects
can be identified and replicated pharmacologically.
Conflict of interest
The authors declare no conflict of interest.
References
1 Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL,
Anis AH. The incidence of co-morbidities related to obesity and
overweight: a systematic review and meta-analysis. BMC Public
Health 2009; 9: 88.
2 Lenard NR, Berthoud HR. Central and peripheral regulation
of food intake and physical activity: pathways and genes.
Obesity (Silver Spring) 2008; 16 (Suppl 3): S11–S22.
3 Berthoud HR, Morrison C. The brain, appetite, and obesity.
Annu Rev Psychol 2008; 59: 55–92.
4 Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez
C et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12:
962–971.
5 Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W,
Fahrbach K et al. Bariatric surgery: a systematic review and metaanalysis. JAMA 2004; 292: 1724–1737.
6 Brolin RE, LaMarca LB, Kenler HA, Cody RP. Malabsorptive
gastric bypass in patients with superobesity. J Gastrointest Surg
2002; 6: 195–203;discussion 204-5.
7 Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass
for obesity: mechanisms of weight loss and diabetes resolution.
J Clin Endocrinol Metab 2004; 89: 2608–2615.
8 Tadross JA, le Roux CW. The mechanisms of weight loss after
bariatric surgery. Int J Obes (London) 2009; 33 (Suppl 1): S28–S32.
International Journal of Obesity
Gut peptides in bariatric surgery
CN Ochner et al
10
9 Orlando FA, Goncalves CG, George ZM, Halverson JD,
Cunningham PR, Meguid MM. Neurohormonal pathways
regulating food intake and changes after Roux-en-Y gastric
bypass. Surg Obes Relat Dis 2005; 1: 486–495.
10 Doucet E, Cameron J. Appetite control after weight loss: what is
the role of bloodborne peptides? Appl Physiol Nutr Metab 2007;
32: 523–532.
11 Batterham RL, ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ,
Withers DJ et al. PYY modulation of cortical and hypothalamic
brain areas predicts feeding behaviour in humans. Nature 2007;
450: 106–109.
12 Balsiger BM, Poggio JL, Mai J, Kelly KA, Sarr MG. Ten and more
years after vertical banded gastroplasty as primary operation for
morbid obesity. J Gastrointest Surg 2000; 4: 598–605.
13 Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity.
Eur J Endocrinol 2008; 158: 135–145.
14 Marceau P, Hould FS, Simard S, Lebel S, Bourque RA, Potvin M
et al. Biliopancreatic diversion with duodenal switch.
World J Surg 1998; 22: 947–954.
15 Poves I, Cabrera M, Maristany C, Coma A, Ballesta-Lopez C.
Gastrointestinal quality of life after laparoscopic Roux-en-Y
gastric bypass. Obes Surg 2006; 16: 19–23.
16 Wren AM, Bloom SR. Gut hormones and appetite control.
Gastroenterology 2007; 132: 2116–2130.
17 Arora S, Anubhuti. Role of neuropeptides in appetite regulation
and obesityFa review. Neuropeptides 2006; 40: 375–401.
18 Geliebter A. Gastric distension and gastric capacity in relation to
food intake in humans. Physiol Behav 1988; 44: 665–668.
19 Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB.
GhrelinFa hormone with multiple functions. Front Neuroendocrinol 2004; 25: 27–68.
20 Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of
food intake. Nutr Metab Cardiovasc Dis 2008; 18: 158–168.
21 Olszewski PK, Li D, Grace MK, Billington CJ, Kotz CM,
Levine AS. Neural basis of orexigenic effects of ghrelin acting
within lateral hypothalamus. Peptides 2003; 24: 597–602.
22 Bloomgarden ZT. Gut hormones, obesity, polycystic ovarian
syndrome, malignancy, and lipodystrophy syndromes. Diabetes
Care 2007; 30: 1934–1939.
23 Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in
rodents. Nature 2000; 407: 908–913.
24 Nonogaki K. Ghrelin and feedback systems. Vitam Horm 2008;
77: 149–170.
25 Garcia-Unzueta MT, Fernandez-Santiago R, Dominguez-Diez A,
Vazquez-Salvi L, Fernandez-Escalante JC, Amado JA. Fasting
plasma ghrelin levels increase progressively after biliopancreatic
diversion: one-year follow-up. Obes Surg 2005; 15: 187–190.
26 Geloneze B, Tambascia MA, Pilla VF, Geloneze SR, Repetto EM,
Pareja JC. Ghrelin: a gut-brain hormone: effect of gastric bypass
surgery. Obes Surg 2003; 13: 17–22.
27 Bohdjalian A, Langer FB, Shakeri-Leidenmuhler S, Gfrerer L,
Ludvik B, Zacherl J et al. Sleeve gastrectomy as sole and
definitive bariatric procedure: 5-year results for weight loss
and ghrelin. Obes Surg 2010; 20: 535–540.
28 Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX,
Zacherl J, Wenzl E et al. Sleeve gastrectomy and gastric banding:
effects on plasma ghrelin levels. Obes Surg 2005; 15: 1024–1029.
29 Depaula AL, Macedo AL, Schraibman V, Mota BR, Vencio S.
Hormonal evaluation following laparoscopic treatment of type
2 diabetes mellitus patients with BMI 20-34. Surg Endosc 2008;
23: 1724–1732.
30 Peterli R, Wolnerhanssen B, Peters T, Devaux N, Kern B,
Christoffel-Courtin C et al. Improvement in glucose metabolism
after bariatric surgery: comparison of laparoscopic Roux-en-Y
gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250: 234–241.
31 Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK.
Weight loss, appetite suppression, and changes in fasting and
postprandial ghrelin and peptide-YY levels after Roux-en-Y
International Journal of Obesity
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
gastric bypass and sleeve gastrectomy: a prospective, double
blind study. Ann Surg 2008; 247: 401–407.
Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R,
Buranyi B et al. Impact of laparoscopic adjustable gastric
banding on plasma ghrelin, eating behaviour and body weight.
Eur J Clin Invest 2004; 34: 549–554.
Uzzan B, Catheline JM, Lagorce C, Airinei G, Bon C, Cohen R
et al. Expression of ghrelin in fundus is increased after
gastric banding in morbidly obese patients. Obes Surg 2007;
17: 1159–1164.
Nijhuis J, van Dielen FM, Buurman WA, Greve JW. Ghrelin,
leptin and insulin levels after restrictive surgery: a 2-year
follow-up study. Obes Surg 2004; 14: 783–787.
Stoeckli R, Chanda R, Langer I, Keller U. Changes of body
weight and plasma ghrelin levels after gastric banding and
gastric bypass. Obes Res 2004; 12: 346–350.
Foschi D, Corsi F, Rizzi A, Asti E, Carsenzuola V, Vago T et al.
Vertical banded gastroplasty modifies plasma ghrelin secretion
in obese patients. Obes Surg 2005; 15: 1129–1132.
Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos
JG, Papavramidis ST. Serum ghrelin, leptin and adiponectin
levels before and after weight loss: comparison of three
methods of treatmentFa prospective study. Obes Surg 2006;
16: 1425–1432.
Foschi D, Corsi F, Colombo F, Vago T, Bevilaqua M, Rizzi A et al.
Different effects of vertical banded gastroplasty and Roux-en-Y
gastric bypass on meal inhibition of ghrelin secretion in
morbidly obese patients. J Invest Surg 2008; 21: 77–81.
Shak JR, Roper J, Perez-Perez GI, Tseng CH, Francois F,
Gamagaris Z et al. The effect of laparoscopic gastric banding
surgery on plasma levels of appetite-control, insulinotropic, and
digestive hormones. Obes Surg 2008; 18: 1089–1096.
Ram E, Vishne T, Diker D, Gal-Ad I, Maayan R, Lerner I et al.
Impact of gastric banding on plasma ghrelin, growth hormone,
cortisol, DHEA and DHEA-S levels. Obes Surg 2005; 15:
1118–1123.
Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas
R et al. Prospective study of gut hormone and metabolic
changes after adjustable gastric banding and Roux-en-Y gastric
bypass. Int J Obes (London) 2009; 33: 786–795.
Garcia de la Torre N, Rubio MA, Bordiu E, Cabrerizo L, Aparicio
E, Hernandez C et al. Effects of weight loss after bariatric surgery
for morbid obesity on vascular endothelial growth factor-A,
adipocytokines, and insulin. J Clin Endocrinol Metab 2008; 93:
4276–4281.
Lin E, Gletsu N, Fugate K, McClusky D, Gu LH, Zhu JL et al.
The effects of gastric surgery on systemic ghrelin levels in the
morbidly obese. Arch Surg 2004; 139: 780–784.
Fruhbeck G, Diez-Caballero A, Gil MJ, Montero I, GomezAmbrosi J, Salvador J et al. The decrease in plasma ghrelin
concentrations following bariatric surgery depends on the
functional integrity of the fundus. Obes Surg 2004; 14: 606–612.
Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, OliveroRivera L et al. Differential effects of gastric bypass and
banding on circulating gut hormone and leptin levels.
Obesity (Silver Spring) 2006; 14: 1553–1561.
Fruhbeck G, Rotellar F, Hernandez-Lizoain JL, Gil MJ, GomezAmbrosi J, Salvador J et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined
by weight loss or changes in insulinemia. Obes Surg 2004; 14:
1208–1215.
Morinigo R, Casamitjana R, Moize V, Lacy AM, Delgado S,
Gomis R et al. Short-term effects of gastric bypass surgery
on circulating ghrelin levels. Obes Res 2004; 12: 1108–1116.
Sundbom M, Holdstock C, Engstrom BE, Karlsson FA.
Early changes in ghrelin following Roux-en-Y gastric bypass:
influence of vagal nerve functionality? Obes Surg 2007; 17:
304–310.
Gut peptides in bariatric surgery
CN Ochner et al
11
49 Pardina E, Lopez-Tejero MD, Llamas R, Catalan R, Galard R,
Allende H et al. Ghrelin and apolipoprotein AIV levels show
opposite trends to leptin levels during weight loss in morbidly
obese patients. Obes Surg 2009; 19: 1414–1423.
50 Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida JM,
Garcia-Arnes J, Gallego-Perales JL, Rivas-Marin J et al. Different
effect of laparoscopic Roux-en-Y gastric bypass and open
biliopancreatic diversion of Scopinaro on serum PYY and
ghrelin levels. Obes Surg 2008; 18: 1424–1429.
51 Bose M, Machineni S, Olivan B, Teixeira J, McGinty JJ, Bawa B
et al. Superior appetite hormone profile after equivalent weight
loss by gastric bypass compared to gastric banding. Obesity
(Silver Spring) 2010; 18: 1085–1091.
52 Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger
EP et al. Plasma ghrelin levels after diet-induced weight loss
or gastric bypass surgery. N Engl J Med 2002; 346: 1623–1630.
53 Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E,
Goldfine A. Serum ghrelin levels in response to glucose load in
obese subjects post-gastric bypass surgery. Obes Res 2003; 11:
919–924.
54 Fruhbeck G, Diez Caballero A, Gil MJ. Fundus functionality and
ghrelin concentrations after bariatric surgery. N Engl J Med 2004;
350: 308–309.
55 Chan JL, Mun EC, Stoyneva V, Mantzoros CS, Goldfine AB.
Peptide YY levels are elevated after gastric bypass surgery. Obesity
(Silver Spring) 2006; 14: 194–198.
56 Rodieux F, Giusti V, D’Alessio DA, Suter M, Tappy L. Effects of
gastric bypass and gastric banding on glucose kinetics and gut
hormone release. Obesity (Silver Spring) 2008; 16: 298–305.
57 Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG,
Aylwin SJ. Progressive rise in gut hormone levels after Rouxen-Y gastric bypass suggests gut adaptation and explains altered
satiety. Br J Surg 2006; 93: 210–215.
58 Adami GF, Cordera R, Marinari G, Lamerini G, Andraghetti G,
Scopinaro N. Plasma ghrelin concentratin in the short-term
following biliopancreatic diversion. Obes Surg 2003; 13:
889–892.
59 Adami GF, Cordera R, Andraghetti G, Camerini GB, Marinari
GM, Scopinaro N. Changes in serum ghrelin concentration
following biliopancreatic diversion for obesity. Obes Res 2004;
12: 684–687.
60 Valera Mora ME, Manco M, Capristo E, Guidone C, Iaconelli A,
Gniuli D et al. Growth hormone and ghrelin secretion
in severely obese women before and after bariatric surgery.
Obesity (Silver Spring) 2007; 15: 2012–2018.
61 Holdstock C, Engstrom BE, Ohrvall M, Lind L, Sundbom M,
Karlsson FA. Ghrelin and adipose tissue regulatory peptides:
effect of gastric bypass surgery in obese humans. J Clin
Endocrinol Metab 2003; 88: 3177–3183.
62 Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K.
Plasma acylation-stimulating protein, adiponectin, leptin, and
ghrelin before and after weight loss induced by gastric bypass
surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;
88: 1594–1602.
63 Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE,
Frayo RS et al. Elevated plasma ghrelin levels in Prader Willi
syndrome. Nat Med 2002; 8: 643–644.
64 Thaler JP, Cummings DE. Minireview: hormonal and metabolic
mechanisms of diabetes remission after gastrointestinal surgery.
Endocrinology 2009; 150: 2518–2525.
65 le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM,
Ghatei MA et al. Ghrelin does not stimulate food intake
in patients with surgical procedures involving vagotomy.
J Clin Endocrinol Metab 2005; 90: 4521–4524.
66 Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A,
Matsuo H et al. The role of the gastric afferent vagal nerve in
ghrelin-induced feeding and growth hormone secretion in rats.
Gastroenterology 2002; 123: 1120–1128.
67 Williams DL, Grill HJ, Cummings DE, Kaplan JM. Vagotomy
dissociates short- and long-term controls of circulating ghrelin.
Endocrinology 2003; 144: 5184–5187.
68 Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P,
Fairclough P et al. The tissue distribution of the mRNA
of ghrelin and subtypes of its receptor, GHS-R, in humans.
J Clin Endocrinol Metab 2002; 87: 2988.
69 Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS,
Suganuma T et al. Ghrelin, a novel growth hormone-releasing
acylated peptide, is synthesized in a distinct endocrine cell type
in the gastrointestinal tracts of rats and humans. Endocrinology
2000; 141: 4255–4261.
70 Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and desacyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000; 279: 909–913.
71 Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y
et al. Stomach regulates energy balance via acylated ghrelin and
desacyl ghrelin. Gut 2005; 54: 18–24.
72 Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M
et al. Non-acylated ghrelin counteracts the metabolic but not
the neuroendocrine response to acylated ghrelin in humans.
J Clin Endocrinol Metab 2004; 89: 3062–3065.
73 Gauna C, Delhanty PJ, Hofland LJ, Janssen JA, Broglio F, Ross RJ
et al. Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits,
glucose output by primary hepatocytes. J Clin Endocrinol Metab
2005; 90: 1055–1060.
74 Weickert MO, Loeffelholz CV, Arafat AM, Schofl C, Otto B,
Spranger J et al. Euglycemic hyperinsulinemia differentially
modulates circulating total and acylated-ghrelin in humans.
J Endocrinol Invest 2008; 31: 119–124.
75 Holmes E, Davies I, Lowe G, Ranganath LR. Circulating
ghrelin exists in both lipoprotein bound and free forms.
Ann Clin Biochem 2009; 46: 514–516.
76 Weickert MO, Spranger J, Holst JJ, Otto B, Koebnick C, Mohlig M
et al. Wheat-fibre-induced changes of postprandial peptide YY
and ghrelin responses are not associated with acute alterations
of satiety. Br J Nutr 2006; 96: 795–798.
77 Lomenick JP, Melguizo MS, Mitchell SL, Summar ML, Anderson
JW. Effects of meals high in carbohydrate, protein, and fat
on ghrelin and peptide YY secretion in prepubertal children.
J Clin Endocrinol Metab 2009; 94: 4463–4471.
78 Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA,
Dakin CL et al. Gut hormone PYY(3-36) physiologically inhibits
food intake. Nature 2002; 418: 650–654.
79 Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I.
Distribution, release and actions. Obes Surg 2006; 16: 651–658.
80 Unniappan S, McIntosh CH, Demuth HU, Heiser U, Wolf R,
Kieffer TJ. Effects of dipeptidyl peptidase IV on the satiety
actions of peptide YY. Diabetologia 2006; 49: 1915–1923.
81 Chelikani PK, Haver AC, Reidelberger RD. Comparison of the
inhibitory effects of PYY(3-36) and PYY(1-36) on gastric
emptying in rats. Am J Physiol Regul Integr Comp Physiol 2004;
287: R1064–R1070.
82 Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A. Effects of
PYY1-36 and PYY3-36 on appetite, energy intake, energy
expenditure, glucose and fat metabolism in obese and lean
subjects. Am J Physiol Endocrinol Metab 2007; 292: E1062–E1068.
83 Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL,
O’Rahilly S. Acute effects of PYY3-36 on food intake and
hypothalamic neuropeptide expression in the mouse. Biochem
Biophys Res Commun 2003; 311: 915–919.
84 Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ,
Frost GS et al. Inhibition of food intake in obese subjects by
peptide YY3-36. N Engl J Med 2003; 349: 941–948.
85 le Roux CW, Bloom SR. Peptide YY, appetite and food intake.
Proc Nutr Soc 2005; 64: 213–216.
86 Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ,
Tatemoto K et al. Effect of peptide YY on gastric, pancreatic, and
biliary function in humans. Gastroenterology 1985; 89: 494–499.
International Journal of Obesity
Gut peptides in bariatric surgery
CN Ochner et al
12
87 Lin HC, Chey WY. Cholecystokinin and peptide YY are released
by fat in either proximal or distal small intestine in dogs.
Regul Pept 2003; 114: 131–135.
88 Pfluger PT, Kampe J, Castaneda TR, Vahl T, D’Alessio DA,
Kruthaupt T et al. Effect of human body weight changes
on circulating levels of peptide YY and peptide YY3-36.
J Clin Endocrinol Metab 2007; 92: 583–588.
89 Wynne K, Bloom SR. The role of oxyntomodulin and peptide
tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract
Endocrinol Metab 2006; 2: 612–620.
90 Reinehr T, Roth CL, Schernthaner GH, Kopp HP, Kriwanek S,
Schernthaner G. Peptide YY and glucagon-like peptide-1 in
morbidly obese patients before and after surgically induced
weight loss. Obes Surg 2007; 17: 1571–1577.
91 Alvarez Bartolome M, Borque M, Martinez-Sarmiento J,
Aparicio E, Hernandez C, Cabrerizo L et al. Peptide YY secretion
in morbidly obese patients before and after vertical banded
gastroplasty. Obes Surg 2002; 12: 324–327.
92 Valderas JP, Irribarra V, Boza C, de la Cruz R, Liberona Y, Acosta
AM et al. Medical and surgical treatments for obesity have
opposite effects on peptide YY and appetite: a prospective study
controlled for weight loss. J Clin Endocrinol Metab 2010; 95:
1069–1075.
93 le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F,
Prasad V et al. Gut hormone profiles following bariatric surgery
favor an anorectic state, facilitate weight loss, and improve
metabolic parameters. Ann Surg 2006; 243: 108–114.
94 Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL
et al. Glucagon-like peptide-1, peptide YY, hunger, and
satiety after gastric bypass surgery in morbidly obese subjects.
J Clin Endocrinol Metab 2006; 91: 1735–1740.
95 Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL
et al. Effects of Roux-en-Y gastric bypass surgery on fasting
and postprandial concentrations of plasma ghrelin, peptide YY,
and insulin. J Clin Endocrinol Metab 2005; 90: 359–365.
96 Riediger T, Bothe C, Becskei C, Lutz TA. Peptide YY directly
inhibits ghrelin-activated neurons of the arcuate nucleus and
reverses fasting-induced c-Fos expression. Neuroendocrinology
2004; 79: 317–326.
97 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev
2007; 87: 1409–1439.
98 Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide
containing pathways in the regulation of feeding behaviour.
Int J Obes Relat Metab Disord 2001; 25 (Suppl 5): S42–S47.
99 Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M
et al. Prandial subcutaneous injections of glucagon-like peptide1 cause weight loss in obese human subjects. Br J Nutr 2004; 91:
439–446.
100 Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J,
Astrup A. The role of postprandial releases of insulin and
incretin hormones in meal-induced satietyFeffect of obesity
and weight reduction. Int J Obes Relat Metab Disord 2001; 25:
1206–1214.
101 Valverde I, Puente J, Martin-Duce A, Molina L, Lozano O,
Sancho V et al. Changes in glucagon-like peptide-1 (GLP-1)
secretion after biliopancreatic diversion or vertical banded
gastroplasty in obese subjects. Obes Surg 2005; 15: 387–397.
102 Morinigo R, Vidal J, Lacy AM, Delgado S, Casamitjana R, Gomis
R. Circulating peptide YY, weight loss, and glucose homeostasis
after gastric bypass surgery in morbidly obese subjects. Ann Surg
2008; 247: 270–275.
103 le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A,
Laurenius A et al. Gut hormones as mediators of appetite and
weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246:
780–785.
104 Bose M, Olivan B, Teixeira J, Pi-Sunyer FX, Laferrère B. Do
Incretins play a role in the remission of type 2 diabetes
after gastric bypass surgery: What are the evidence? Obes Surg
2009; 19: 217–229.
International Journal of Obesity
105 Baldinger M, Rubin R, Wright N, Flancbaum A, Geliebter A.
Change in hunger, fullness, ghrelin, PYY and GLP-1 in relation
to a fixed test meal pre and post Rou-en-Y gastric bypass
(RYGBS). Appetite 2007; 49: 277 (abstract).
106 de Carvalho CP, Marin DM, de Souza AL, Pareja JC, Chaim EA,
de Barros Mazon S et al. GLP-1 and adiponectin: effect of weight
loss after dietary restriction and gastric bypass in morbidly
obese patients with normal and abnormal glucose metabolism.
Obes Surg 2009; 19: 313–320.
107 Chandra R, Liddle RA. Cholecystokinin. Curr Opin Endocrinol
Diabetes Obes 2007; 14: 63–67.
108 Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA.
Cholecystokinin bioactivity in human plasma. Molecular forms,
responses to feeding, and relationship to gallbladder contraction. J Clin Invest 1985; 75: 1144–1152.
109 Suzuki S, Ramos EJ, Goncalves CG, Chen C, Meguid MM.
Changes in GI hormones and their effect on gastric emptying
and transit times after Roux-en-Y gastric bypass in rat model.
Surgery 2005; 138: 283–290.
110 Rehfeld JF. Accurate measurement of cholecystokinin in plasma.
Clin Chem 1998; 44: 991–1001.
111 Kellum JM, Kuemmerle JF, O’Dorisio TM, Rayford P, Martin D,
Engle K et al. Gastrointestinal hormone responses to meals
before and after gastric bypass and vertical banded gastroplasty.
Ann Surg 1990; 211: 763–770;discussion 770-1.
112 Foschi D, Corsi F, Pisoni L, Vago T, Bevilacqua M, Asti E et al.
Plasma cholecystokinin levels after vertical banded gastroplasty:
effects of an acidified meal. Obes Surg 2004; 14: 644–647.
113 Konturek JW. Cholecystokinin in the control of gastric acid and
plasma gastrin and somatostatin secretion in healthy subjects
and duodenal ulcer patients before and after eradication of
Helicobacter pylori. J Physiol Pharmacol 1994; 45 (4 Suppl 1): 3–66.
114 Katsusuke S, Takeuchi T, Watanabe S, Nishiwaki H. Postprandial
plasma cholecystokinin response in patients after gastrectomy
and pancreatoduodenectomy. Am J Gastroenterol 2008; 81:
1038–1042.
115 Baskin DG, Figlewicz Lattemann D, Seeley RJ, Woods SC, Porte Jr
D, Schwartz MW. Insulin and leptin: dual adiposity signals to
the brain for the regulation of food intake and body weight.
Brain Res 1999; 848: 114–123.
116 Wang L, Barachina MD, Martinez V, Wei JY, Tache Y. Synergistic
interaction between CCK and leptin to regulate food intake.
Regul Pept 2000; 92: 79–85.
117 Chi MM, Fan G, Fox EA. Increased short-term food satiation and
sensitivity to cholecystokinin in neurotrophin-4 knock-in mice.
Am J Physiol Regul Integr Comp Physiol 2004; 287: R1044–R1053.
118 Barrachina MD, Martinez V, Wang L, Wei JY, Tache Y. Synergistic
interaction between leptin and cholecystokinin to reduce
short-term food intake in lean mice. Proc Natl Acad Sci USA
1997; 94: 10455–10460.
119 Weickert MO, Mohlig M, Spranger J, Schofl C, Loeffelholz CV,
Riepl RL et al. Effects of euglycemic hyperinsulinemia and lipid
infusion on circulating cholecystokinin. J Clin Endocrinol Metab
2008; 93: 2328–2333.
120 Woods SC, D’Alessio DA. Central control of body weight and
appetite. J Clin Endocrinol Metab 2008; 93 (11 Suppl 1): S37–S50.
121 Wang MY, Lee Y, Unger RH. Novel form of lipolysis induced by
leptin. J Biol Chem 1999; 274: 17541–17544.
122 Fried SK, Ricci MR, Russell CD, Laferrère B. Regulation of leptin
production in humans. J Nutr 2000; 130: 3127S–3131S.
123 Hukshorn CJ, van Dielen FM, Buurman WA, WesterterpPlantenga MS, Campfield LA, Saris WH. The effect of pegylated
recombinant human leptin (PEG-OB) on weight loss and
inflammatory status in obese subjects. Int J Obes Relat Metab
Disord 2002; 26: 504–509.
124 Cammisotto PG, Bendayan M. Leptin secretion by white adipose
tissue and gastric mucosa. Histol Histopathol 2007; 22: 199–210.
125 Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B.
Increased plasma visfatin concentrations in morbidly obese
Gut peptides in bariatric surgery
CN Ochner et al
13
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
subjects are reduced after gastric banding. J Clin Endocrinol Metab
2006; 91: 1578–1581.
DePaula AL, Macedo AL, Schraibman V, Mota BR, Vencio S.
Hormonal evaluation following laparoscopic treatment of type
2 diabetes mellitus patients with BMI 20-34. Surg Endosc 2009;
23: 1724–1732.
Pardina E, Lopez-Tejero MD, Llamas R, Catalan R, Galard R,
Allende H et al. Ghrelin and apolipoprotein AIV levels show
opposite trends to leptin levels during weight loss in morbidly
obese patients. Obes Surg 2009; 19: 1414–1423.
Trakhtenbroit MA, Leichman JG, Algahim MF, Miller III CC,
Moody FG, Lux TR et al. Body weight, insulin resistance, and
serum adipokine levels 2 years after 2 types of bariatric surgery.
Am J Med 2009; 122: 435–442.
Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J
et al. The early effect of the Roux-en-Y gastric bypass on
hormones involved in body weight regulation and glucose
metabolism. Ann Surg 2004; 240: 236–242.
Kotidis EV, Koliakos G, Papavramidis TS, Papavramidis ST.
The effect of biliopancreatic diversion with pylorus-preserving
sleeve gastrectomy and duodenal switch on fasting serum
ghrelin, leptin and adiponectin levels: is there a hormonal
contribution to the weight-reducing effect of this procedure?
Obes Surg 2006; 16: 554–559.
Foschi D, Corsi F, Pisoni L, Vago T, Bevilacqua M, Trabucchi A
et al. Plasma leptin levels after vertical banded gastroplasty
for morbid obesity: effects of an acidified meal. Obes Surg 2003;
13: 874–878.
Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of
sibutramine and low-dose leptin in treatment of diet-induced
obesity in rats. Metabolism 2001; 50: 889–893.
Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J.
Leptin reverses weight loss-induced changes in regional neural
activity responses to visual food stimuli. J Clin Invest 2008; 118:
2583–2591.
Maffeis C, Manfredi R, Trombetta M, Sordelli S, Storti M, Benuzzi
T et al. Insulin sensitivity is correlated with subcutaneous but not
visceral body fat in overweight and obese prepubertal children.
J Clin Endocrinol Metab 2008; 93: 2122–2128.
Bjorntorp P. Obesity, atherosclerosis and diabetes mellitus.
Verh Dtsch Ges Inn Med 1987; 93: 443–448.
Rushing PA, Lutz TA, Seeley RJ, Woods SC. Amylin and insulin
interact to reduce food intake in rats. Horm Metab Res 2000; 32:
62–65.
Ballantyne GH, Farkas D, Laker S, Wasielewski A. Short-term
changes in insulin resistance following weight loss surgery for
morbid obesity: laparoscopic adjustable gastric banding versus
laparoscopic Roux-en-Y gastric bypass. Obes Surg 2006; 16:
1189–1197.
Dixon AF, Dixon JB, O’Brien PE. Laparoscopic adjustable gastric
banding induces prolonged satiety: a randomized blind
crossover study. J Clin Endocrinol Metab 2005; 90: 813–819.
Lee WJ, Lee YC, Ser KH, Chen JC, Chen SC. Improvement of
insulin resistance after obesity surgery: a comparison of gastric
banding and bypass procedures. Obes Surg 2008; 18: 1119–1125.
Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D,
Mari A et al. Mechanisms of recovery from type 2 diabetes after
malabsorptive bariatric surgery. Diabetes 2006; 55: 2025–2031.
Morrow J, Gluck M, Lorence M, Flancbaum L, Geliebter A. Night
eating status and influence on body weight, body image,
hunger, and cortisol pre- and post- Roux-en-Y Gastric Bypass
(RYGB) surgery. Eat Weight Disord 2008; 13: e96–e99.
Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of
troglitazone on blood concentrations of plasminogen activator
inhibitor 1 in patients with type 2 diabetes and in lean and
obese normal subjects. Diabetes 2000; 49: 633–639.
Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M
et al. Characterization of the effects of pancreatic polypeptide in
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
the regulation of energy balance. Gastroenterology 2003; 124:
1325–1336.
Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH,
Bell JD et al. Differential hypothalamic neuronal activation
following peripheral injection of GLP-1 and oxyntomodulin in
mice detected by manganese-enhanced magnetic resonance
imaging. Biochem Biophys Res Commun 2006; 350: 298–306.
Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB
et al. Adiponectin acts in the brain to decrease body weight.
Nat Med 2004; 10: 524–529.
Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ,
Morris A et al. Central administration of resistin promotes shortterm satiety in rats. Eur J Endocrinol 2005; 153: R1–R5.
Lutz TA. Pancreatic amylin as a centrally acting satiating
hormone. Curr Drug Targets 2005; 6: 181–189.
Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, Barnes AJ.
Distribution and release of human pancreatic polypeptide.
Gut 1976; 17: 940–944.
Schrumpf E, Bergan A, Djoseland O, Fausa O, Flaten O,
Skagen DW et al. The effect of gastric bypass operation on
glucose tolerance in obesity. Scand J Gastroenterol Suppl 1985;
107: 24–31.
Meryn S, Stein D, Straus EW. Fasting- and meal-stimulated
peptide hormone concentrations before and after gastric surgery
for morbid obesity. Metabolism 1986; 35: 798–802.
Meryn S, Stein D, Straus EW. Pancreatic polypeptide, pancreatic
glucagon and enteroglucagon in morbid obesity and following
gastric bypass operation. Int J Obes 1986; 10: 37–42.
Amland PF, Jorde R, Giercksky KE, Burhol PG. Diurnal GIP, PP
and insulin levels in morbid obesity before and after stapled
gastric partitioning with gastro-gastrostomy. Int J Obes 1984; 8:
117–122.
Amland PF, Jorde R, Kildebo S, Burhol PG, Giercksky KE. Effects
of a gastric partitioning operation for morbid obesity on the
secretion of gastric inhibitory polypeptide and pancreatic
polypeptide. Scand J Gastroenterol 1984; 19: 857–861.
Civalleri D, Bloom SR, Sarson DL, Gianetta E, Bonalumi U,
Friedman D et al. Behavior of plasma pancreatic polypeptides
and motilin in obese patients subjected to biliopancreatic
bypass]. Boll Soc Ital Biol Sper 1980; 56: 1929–1935.
Dubrasquet M, Bataille D, Gespach C. Oxyntomodulin
(glucagon-37 or bioactive enteroglucagon): a potent inhibitor
of pentagastrin-stimulated acid secretion in rats. Biosci Rep 1982;
2: 391–395.
Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A,
Patterson M et al. Oxyntomodulin suppresses appetite and
reduces food intake in humans. J Clin Endocrinol Metab 2003; 88:
4696–4701.
Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV.
Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding
to liver cell membranes, effects on isolated perfused pig
pancreas, and secretion from isolated perfused lower small
intestine of pigs. Regul Pept 1988; 21: 151–166.
Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM
et al. Oxyntomodulin inhibits food intake in the rat.
Endocrinology 2001; 142: 4244–4250.
Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA,
Patterson M et al. Peripheral oxyntomodulin reduces food
intake and body weight gain in rats. Endocrinology 2004; 145:
2687–2695.
Strader AD, Vahl TP, Jandacek RJ, Woods SC, D’Alessio DA,
Seeley RJ. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis
in rats. Am J Physiol Endocrinol Metab 2005; 288: E447–E453.
Barry RE, Barisch J, Bray GA, Sperling MA, Morin RJ, Benfield J.
Intestinal adaptation after jejunoileal bypass in man. Am J Clin
Nutr 1977; 30: 32–42.
Holst JJ, Sorensen TI, Andersen AN, Stadil F, Andersen B,
Lauritsen KB et al. Plasma enteroglucagon after jejunoileal
International Journal of Obesity
Gut peptides in bariatric surgery
CN Ochner et al
14
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol
1979; 14: 205–207.
Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H,
Billington CJ et al. Adipokine response in diabetics
and nondiabetics following the Roux-en-Y gastric bypass: a
preliminary study. J Surg Res 2007; 142: 295–300.
Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB
et al. Regulation of resistin expression and circulating levels in
obesity, diabetes, and fasting. Diabetes 2004; 53: 1671–1679.
Osawa H, Ochi M, Tabara Y, Kato K, Yamauchi J, Takata Y et al.
Serum resistin is positively correlated with the accumulation of
metabolic syndrome factors in type 2 diabetes. Clin Endocrinol
(Oxf) 2008; 69: 74–80.
Gokce N, Vita JA, McDonnell M, Forse AR, Istfan N, Stoeckl M
et al. Effect of medical and surgical weight loss on endothelial
vasomotor function in obese patients. Am J Cardiol 2005; 95:
266–268.
Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H,
Billington CJ et al. Entero-endocrine changes after gastric bypass
in diabetic and nondiabetic patients: a preliminary study. J Surg
Res 2007; 141: 31–39.
Bose M, Teixeira J, Olivan B, Scherer PE, Pi-Sunyer FX, Bawa B
et al. Weight loss and incretin responsiveness improve glucose
control independently after gastric bypass surgery. J Diabetes
2010; 2: 47–55.
Cummings DE, Shannon MH. Roles for ghrelin in the regulation
of appetite and body weight. Arch Surg 2003; 138: 389–396.
Vincent RP, le Roux CW. Changes in gut hormones after
bariatric surgery. Clin Endocrinol (Oxf) 2008; 69: 173–179.
Sugerman HJ, Starkey JV, Birkenhauer R. A randomized
prospective trial of gastric bypass versus vertical banded
gastroplasty for morbid obesity and their effects on sweets
versus non-sweets eaters. Ann Surg 1987; 205: 613–624.
Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman
HJ, Livingston EH et al. Meta-analysis: surgical treatment of
obesity. Ann Intern Med 2005; 142: 547–559.
Mun EC, Blackburn GL, Matthews JB. Current status of medical
and surgical therapy for obesity. Gastroenterology 2001; 120:
669–681.
Nightengale ML, Sarr MG, Kelly KA, Jensen MD, Zinsmeister AR,
Palumbo PJ. Prospective evaluation of vertical banded
gastroplasty as the primary operation for morbid obesity.
Mayo Clin Proc 1991; 66: 773–782.
Howard L, Malone M, Michalek A, Carter J, Alger S, Van Woert J.
Gastric bypass and vertical banded gastroplasty- a prospective
randomized comparison and 5-year follow-up. Obes Surg 1995;
5: 55–60.
Naslund I, Wickbom G, Christoffersson E, Agren G. A prospective
randomized comparison of gastric bypass and gastroplasty. Complications and early results. Acta Chir Scand 1986; 152: 681–689.
Brolin RE. Bariatric surgery and long-term control of morbid
obesity. JAMA 2002; 288: 2793–2796.
Faraj M, Jones P, Sniderman AD, Cianflone K. Enhanced dietary
fat clearance in postobese women. J Lipid Res 2001; 42: 571–580.
MacLean LD, Rhode BM, Nohr CW. Long- or short-limb gastric
bypass? J Gastrointest Surg 2001; 5: 525–530.
Naslund I. Gastric bypass versus gastroplasty. A prospective
study of differences in two surgical procedures for morbid
obesity. Acta Chir Scand Suppl 1987; 536: 1–60.
Boza C, Gagner M, Devaud N, Escalona A, Munoz R, Gandarillas
M. Laparoscopic sleeve gastrectomy with ileal transposition
(SGIT): a new surgical procedure as effective as gastric bypass
for weight control in a porcine model. Surg Endosc 2008; 22:
1029–1034.
Koopmans HS, Sclafani A, Fichtner C, Aravich PF. The effects
of ileal transposition on food intake and body weight loss in
VMH-obese rats. Am J Clin Nutr 1982; 35: 284–293.
Koopmans HS, Ferri GL, Sarson DL, Polak JM, Bloom SR. The
effects of ileal transposition and jejunoileal bypass on food
International Journal of Obesity
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
intake and GI hormone levels in rats. Physiol Behav 1984; 33:
601–609.
de Paula AL, Macedo AL, Prudente AS, Queiroz L, Schraibman V,
Pinus J. Laparoscopic sleeve gastrectomy with ileal interposition
(‘neuroendocrine brake’)Fpilot study of a new operation.
Surg Obes Relat Dis 2006; 2: 464–467.
Gagner M. La transposition ile’ale avec ou sans gastrectomy par
laparoscopie chez l’homme (TIG). J Coeliochirurgie 2005; 54: 4–9.
Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a
non-obese animal model of type 2 diabetes: a new perspective
for an old disease. Ann Surg 2004; 239: 1–11.
Stylopoulos N, Hoppin AG, Kaplan LM. Roux-en-Y gastric
bypass enhances energy expenditure and extends lifespan
in diet-induced obese rats. Obesity (Silver Spring) 2009; 17:
1839–1847.
Naslund E, Hellstrom PM, Kral JG. The gut and food intake: an
update for surgeons. J Gastrointest Surg 2001; 5: 556–567.
Flancbaum L, Choban PS, Bradley LR, Burge JC. Changes in
measured resting energy expenditure after Roux-en-Y gastric
bypass for clinically severe obesity. Surgery 1997; 122: 943–949.
Carrasco F, Papapietro K, Csendes A, Salazar G, Echenique C,
Lisboa C et al. Changes in resting energy expenditure and body
composition after weight loss following Roux-en-Y gastric
bypass. Obes Surg 2007; 17: 608–616.
de Castro Cesar M, de Lima Montebelo MI, Rasera Jr I,
de Oliveira Jr AV, Gomes Gonelli PR, Aparecida Cardoso G.
Effects of Roux-en-Y gastric bypass on resting energy expenditure in women. Obes Surg 2008; 18: 1376–1380.
Xu Y, Ramos EJ, Middleton F, Romanova I, Quinn R, Chen C
et al. Gene expression profiles post Roux-en-Y gastric bypass.
Surgery 2004; 136: 246–252.
Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ,
Salas R et al. Prospective study of gut hormone and metabolic
changes after adjustable gastric banding and Roux-en-Y gastric
bypass. Int J Obes (London) 2009; 33: 786–795.
Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S
et al. Effects of weight loss induced by bariatric surgery on
hepatic adipocytokine expression. J Hepatol 2009; 51: 765–777.
Nijhuis J, van Dielen FM, Fouraschen SM, van den Broek MA,
Rensen SS, Buurman WA et al. Endothelial activation markers
and their key regulators after restrictive bariatric surgery. Obesity
(Silver Spring) 2007; 15: 1395–1399.
Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF,
Schernthaner G. Effects of marked weight loss on plasma levels
of adiponectin, markers of chronic subclinical inflammation
and insulin resistance in morbidly obese women. Int J Obes
(London) 2005; 29: 766–771.
Roth CL, Reinehr T, Schernthaner GH, Kopp HP, Kriwanek S,
Schernthaner G. Ghrelin and obestatin levels in severely obese
women before and after weight loss after Roux-en-Y gastric
bypass surgery. Obes Surg 2009; 19: 29–35.
Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A
et al. Effect of weight loss by gastric bypass surgery versus
hypocaloric diet on glucose and incretin levels in patients with
type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 2479–2485.
Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M,
Mingrone G. First-phase insulin secretion restoration and
differential response to glucose load depending on the route
of administration in type 2 diabetic subjects after bariatric
surgery. Diabetes Care 2009; 32: 375–380.
Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J
et al. Incretin levels and effect are markedly enhanced 1 month
after Roux-en-Y gastric bypass surgery in obese patients with
type 2 diabetes. Diabetes Care 2007; 30: 1709–1716.
Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL.
Hormonal changes after Roux-en Y gastric bypass for morbid
obesity and the control of type-II diabetes mellitus. Am Surg
2004; 70: 1–4; discussion 4-5.